IBB Stock Recent News
IBB LATEST HEADLINES
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
As of the latest data available, the top three holdings in the iShares Biotechnology ETF (NASDAQ: IBB) are: These three companies collectively represent approximately 25.68% of the Biotechnology Sector ETF's total assets. With GILD in top technical position, AMGN and VRTX are also looking interesting.
Biotech stocks have underperformed due to sector rotation, rising rates, and regulatory pressures, but I see a contrarian opportunity emerging. A close look at the recent performance of biotech stocks, the innovative pipeline, and AI-driven process improvements suggests the market may be missing the big picture. Institutional investors are getting back in on the action, evident from the strong Q1 in terms of deal activity.
The stock market doesn't believe the president about prescription drugs.
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.